Transplant Surgery »  Meet the Team »  Hepatology »  Norah A. Terrault, M.D., M.P.H.

Norah A. Terrault, M.D., M.P.H.

Professor of Clinical Medicine & Surgery
Departments of Medicine & Surgery
Director of Viral Hepatitis Research in Liver Transplantation

Contact Information

Academic Office
Division of Gastroenterology
513 Parnassus Avenue, Room S-357
San Francisco, CA 94143-0358
Phone: (415) 476-2227
415-476-0659
norah.terrault@ucsf.edu
 
Open Popup
  • 1985 B.MSc., University of Alberta
  • 1987 M.D., University of Alberta
  • 1997 M.P.H. University of California, Berkeley
  • 1987-88 Internship, University of Toronto
  • 1988-91 Internal Medicine, University of Toronto
  • 1991-93 Gastroenterology, University of Toronto
  • 1994-95 Clinical Hepatology, Division of Gastroenterology, University of Toronto

  • 1995-97 Research Hepatology, Division of Gastroenterology, UCSF Medical Center

  • American Board of Internal Medicine, Internal Medicine
  • American Board of Internal Medicine, Gastroenterology
  • UCSF Liver Center
  • Hepatitis B virus (HBV)
  • Hepatitis C virus (HCV)
  • Liver Injury and Repair

Dr. Norah Terrault is a hepatologist or liver specialist who is recognized internationally for the treatment of viral hepatitis and liver transplantation. Her research includes the study of viral hepatitis and its progression and treatment, especially in liver transplant patients. Her research includes several clinical trials related to preventing and treating chronic hepatitis C and B. Her studies in this area have been presented to the American Association for the Study of Liver Diseases, the leading organization for research in liver disease.

Terrault completed medical training at the University of Alberta and specialty medical training in Internal Medicine and Gastroenterology at the University of Toronto, both in Canada. Her post-doctoral fellowship in hepatology and viral hepatitis was completed at the University of California, San Francisco while earning a concurrent master's degree in public health from the University of California at Berkeley. She joined the medical staff at UCSF Medical Center in 1997.

My research focuses on the natural history and treatment of hepatitis C virus (HCV) and hepatitis B virus (HBV), particularly in special populations, including those undergoing liver transplantation. Work in progress addresses the natural history of post-transplant disease and specific therapies to prevent infection or modify HCV and HBV disease progression and loss of grafts from recurrent disease.

Our virological analyses are focused on characterization of viral mutations that occur in liver transplant recipients receiving antiviral therapies and assessment of the effect of these variant viruses on the natural history and severity of disease post-transplantation. Knowledge of these factors may allow improved organ allocation by identifying subsets of patients with HCV recurrence in liver grafts who would be favorable or unfavorable candidates for retransplantation. 

Most recent publications from a total of 237
  1. Levitsky J, Verna EC, O'Leary JG, Bzowej NH, Moonka DK, Hyland RH, Arterburn S, Dvory-Sobol H, Brainard DM, McHutchison JG, Terrault NA. Perioperative Ledipasvir-Sofosbuvir for HCV in Liver-Transplant Recipients. N Engl J Med. 2016 11 24; 375(21):2106-2108. View in PubMed
  2. Butt Z, Dew MA, Liu Q, Simpson MA, Smith AR, Zee J, Gillespie BW, Abbey SE, Ladner DP, Weinrieb R, Fisher RA, Hafliger S, Terrault N, Burton J, Sherker AH, Di Martini A. Psychological Outcomes of Living Liver Donors from a Multi-Center, Prospective Study: Results from the Adult to Adult Living Donor Liver Transplantation Cohort Study (A2ALL). Am J Transplant. 2016 Nov 19. View in PubMed
  3. Flemming JA, Kim WR, Brosgart CL, Terrault NA. Reduction in liver transplant wait-listing in the era of direct-acting antiviral therapy. Hepatology. 2016 Nov 05. View in PubMed
  4. Reddy KR, Lim JK, Kuo A, Di Bisceglie AM, Galati JS, Morelli G, Everson GT, Kwo PY, Brown RS, Sulkowski MS, Akuschevich L, Lok AS, Pockros PJ, Vainorius M, Terrault NA, Nelson DR, Fried MW, Manns MP. All-oral direct-acting antiviral therapy in HCV-advanced liver disease is effective in real-world practice: observations through HCV-TARGET database. Aliment Pharmacol Ther. 2016 Oct 28. View in PubMed
  5. Terrault NA, Hassanein TI. Management of the patient with SVR. J Hepatol. 2016 Oct; 65(1 Suppl):S120-9. View in PubMed
  6. Terrault NA. Real-World Experiences with Tenofovir Disoproxil Fumarate: Is this the "B-Ticket"? Dig Dis Sci. 2016 Oct; 61(10):2770-2. View in PubMed
  7. Ajmera V, Perito ER, Bass NM, Terrault NA, Yates KP, Gill R, Loomba R, Diehl AM, Aouizerat B. Novel Plasma Biomarkers Associated with Liver Disease Severity in Adults with Nonalcoholic Fatty Liver Disease. Hepatology. 2016 Aug 17. View in PubMed
  8. Yang JD, Abdelmalek MF, Guy CD, Gill RM, Lavine JE, Yates K, Klair J, Terrault NA, Clark JM, Unalp-Arida A, Diehl AM, Suzuki A. Patient Sex, Reproductive Status, and Synthetic Hormone Use Associate With Histologic Severity of Nonalcoholic  Steatohepatitis. Clin Gastroenterol Hepatol. 2016 Aug 12. View in PubMed
  9. Campos-Varela I, Dodge JL, Stock PG, Terrault NA. Key donor factors associated with graft loss among liver transplant recipients with human immunodeficiency virus. Clin Transplant. 2016 Sep; 30(9):1140-5. View in PubMed
  10. Sarkar M, Dodge JL, Roberts JP, Terrault N, Yao F, Mehta N.  Increased hepatocellular carcinoma recurrence in women compared to men with high alpha fetoprotein at liver transplant. Ann Hepatol. 2016 Jul-Aug; 15(4):545-9. View in PubMed
  11. View All Publications
Publications provided by UCSF Profiles, powered by CTSI at UCSF. View profile of Norah A. Terrault, M.D., M.P.H.
Please note: UCSF Profiles publications are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact CTSI for help.

X